Header Logo

Connection

WILLIAM PEACOCK to Natriuretic Peptide, Brain

Back to Details
This is a "connection" page, showing publications WILLIAM PEACOCK has written about Natriuretic Peptide, Brain.
WILLIAM PEACOCK
Connection Strength
4.605
Natriuretic Peptide, Brain
  1. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med. 2011 Sep; 18(9):947-58.
    View in: PubMed
    Score: 0.330
  2. Primary role of B-type natriuretic peptide across the clinical spectrum: from emergency medicine to transitional care and beyond into the community. Congest Heart Fail. 2011 Jan-Feb; 17(1):8-13.
    View in: PubMed
    Score: 0.317
  3. Emergency department perspectives on B-type natriuretic peptide utility. Congest Heart Fail. 2008 Jul-Aug; 14(4 Suppl 1):17-20.
    View in: PubMed
    Score: 0.265
  4. Initial results from the PROACTION study. J Emerg Med. 2006 Nov; 31(4):435-6.
    View in: PubMed
    Score: 0.236
  5. Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE. Cardiology. 2007; 107(1):44-51.
    View in: PubMed
    Score: 0.228
  6. Observation unit treatment of heart failure with nesiritide: results from the proaction trial. J Emerg Med. 2005 Oct; 29(3):243-52.
    View in: PubMed
    Score: 0.219
  7. Current and emerging issues with B-type natriuretic peptide. Roundtable discussion. Congest Heart Fail. 2005 Jul-Aug; 11(4):212-4.
    View in: PubMed
    Score: 0.215
  8. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med. 2005 May; 23(3):327-31.
    View in: PubMed
    Score: 0.213
  9. Nesiritide in congestive heart failure associated with acute coronary syndromes: a pilot study of safety and efficacy. J Card Fail. 2004 Apr; 10(2):120-5.
    View in: PubMed
    Score: 0.197
  10. Acute Emergency Department management of heart failure. Heart Fail Rev. 2003 Oct; 8(4):335-8.
    View in: PubMed
    Score: 0.191
  11. Clinical and economic impact of nesiritide. Am J Health Syst Pharm. 2003 Aug 15; 60 Suppl 4:S21-6.
    View in: PubMed
    Score: 0.189
  12. The B-type natriuretic peptide assay: a rapid test for heart failure. Cleve Clin J Med. 2002 Mar; 69(3):243-51.
    View in: PubMed
    Score: 0.171
  13. sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure. Acta Cardiol. 2020 Dec; 75(8):739-747.
    View in: PubMed
    Score: 0.144
  14. N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The?ICON-RELOADED Study. J Am Coll Cardiol. 2018 03 20; 71(11):1191-1200.
    View in: PubMed
    Score: 0.130
  15. Using galectin-3 to reduce heart failure rehospitalization. Future Cardiol. 2014 Mar; 10(2):221-7.
    View in: PubMed
    Score: 0.098
  16. Differentiation of cardiac and noncardiac dyspnea using bioelectrical impedance vector analysis (BIVA). J Card Fail. 2012 Mar; 18(3):226-32.
    View in: PubMed
    Score: 0.084
  17. Placental growth factor and B-type natriuretic peptide as independent predictors of risk from a multibiomarker panel in suspected acute coronary syndrome (Acute Risk and Related Outcomes Assessed With Cardiac Biomarkers [ARROW]) study. Am J Cardiol. 2011 Mar 15; 107(6):821-6.
    View in: PubMed
    Score: 0.079
  18. Japanese-Western consensus meeting on biomarkers. Int Heart J. 2011; 52(5):253-65.
    View in: PubMed
    Score: 0.079
  19. Serial changes in high-sensitive troponin I predict outcome in patients with decompensated heart failure. Eur J Heart Fail. 2011 Jan; 13(1):37-42.
    View in: PubMed
    Score: 0.079
  20. Hemodynamic changes as a diagnostic tool in acute heart failure--a pilot study. Am J Emerg Med. 2012 Jan; 30(1):174-80.
    View in: PubMed
    Score: 0.078
  21. Acoustic cardiography S3 detection use in problematic subgroups and B-type natriuretic peptide "gray zone": secondary results from the Heart failure and Audicor technology for Rapid Diagnosis and Initial Treatment Multinational Investigation. Am J Emerg Med. 2011 Oct; 29(8):924-31.
    View in: PubMed
    Score: 0.076
  22. Adjusting for clinical covariates improves the ability of B-type natriuretic peptide to distinguish cardiac from non-cardiac dyspnoea: a sub-study of HEARD-IT. Eur J Heart Fail. 2009 Nov; 11(11):1043-9.
    View in: PubMed
    Score: 0.072
  23. Risk stratification for suspected acute coronary syndromes and heart failure in the emergency department. Acute Card Care. 2009; 11(3):138-45.
    View in: PubMed
    Score: 0.069
  24. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008 Sep; 10(9):824-39.
    View in: PubMed
    Score: 0.067
  25. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol. 2008 Aug 12; 52(7):534-40.
    View in: PubMed
    Score: 0.067
  26. Usefulness of serial assessment of natriuretic peptides in the emergency department for patients with acute decompensated heart failure. Congest Heart Fail. 2008 Jul-Aug; 14(4 Suppl 1):21-4.
    View in: PubMed
    Score: 0.066
  27. Natriuretic peptides in acute coronary syndromes: prognostic value and clinical implications. Congest Heart Fail. 2008 Jul-Aug; 14(4 Suppl 1):25-9.
    View in: PubMed
    Score: 0.066
  28. Inpatient monitoring and prognostic importance of B-type natriuretic peptide. Congest Heart Fail. 2008 Jul-Aug; 14(4 Suppl 1):30-4.
    View in: PubMed
    Score: 0.066
  29. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol. 2008 Jan 15; 101(2):231-7.
    View in: PubMed
    Score: 0.064
  30. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007 May 15; 49(19):1943-50.
    View in: PubMed
    Score: 0.061
  31. Clinical and economic benefits of using AUDICOR S3 detection for diagnosis and treatment of acute decompensated heart failure. Congest Heart Fail. 2006 Jul-Aug; 12 Suppl 1:32-6.
    View in: PubMed
    Score: 0.058
  32. Acoustic cardiography in the differential diagnosis of dyspnea. Congest Heart Fail. 2006 Jul-Aug; 12 Suppl 1:41-3.
    View in: PubMed
    Score: 0.058
  33. The combined utility of an S3 heart sound and B-type natriuretic peptide levels in emergency department patients with dyspnea. J Card Fail. 2006 May; 12(4):286-92.
    View in: PubMed
    Score: 0.057
  34. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004 Sep-Oct; 10(5 Suppl 3):1-30.
    View in: PubMed
    Score: 0.051
  35. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004 Feb; 19(2):391-9.
    View in: PubMed
    Score: 0.049
  36. Multiple Cardiac Biomarker Testing Among Patients With Acute Dyspnea From the ICON-RELOADED Study. J Card Fail. 2022 02; 28(2):226-233.
    View in: PubMed
    Score: 0.042
  37. Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. N Engl J Med. 2017 05 18; 376(20):1956-1964.
    View in: PubMed
    Score: 0.030
  38. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH. Eur J Heart Fail. 2015 Dec; 17(12):1271-82.
    View in: PubMed
    Score: 0.027
  39. Capturing the pathophysiology of acute coronary syndromes with circulating biomarkers. Rev Cardiovasc Med. 2010; 11 Suppl 2:S3-12.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.